Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use
Authors:
- Rodger L. BickRBRodger L. Bick
- Eugene P. FrenkelEFEugene P. Frenkel
- Jeanine WalengaJWJeanine Walenga
- Jawed FareedJFJawed Fareed
- Deborah A. HoppensteadtDHDeborah A. Hoppensteadt
- 1 February 2005
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 19 (1) , 1-51
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Unfractionated and Low-Molecular-Weight Heparins, Basic Mechanism of Action and PharmacologySeminars in Cardiothoracic and Vascular Anesthesia, 2003
- The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administrationJACC, 2003
- Low molecular weight heparins: are they interchangeable? NoJournal of Thrombosis and Haemostasis, 2003
- Therapeutic Equivalency of Low-Molecular-Weight HeparinsAnnals of Pharmacotherapy, 2002
- Applying Scientific Criteria to Therapeutic Interchange: A Balanced Analysis of Low-Molecular-Weight HeparinsJournal of Thrombosis and Thrombolysis, 2001
- Effects of various anticoagulant treatments on von Willebrand factor release in unstable anginaJACC, 2000
- Inhibition of thrombin generation by heparin and LMW heparinsBlood Coagulation & Fibrinolysis, 1996
- From the Food and Drug Administration1993
- The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mgThe Journal of Clinical Pharmacology, 1988
- Studies on the Antithrombotic Effects and Pharmacokinetics of Heparin Fractions and FragmentsSeminars in Thrombosis and Hemostasis, 1985